Domatinostat increased the expression of MHC-II on both tumor and immune cells, which is beneficial for CD4+ T cell priming in principle; however, interactions with the LAG3 receptor could subvert the CD4+ T cell response against the tumor [46]. Here, CD4 is linked to neoplasm.